Information

Accutane Side Effects: Should Depression Be A Concern?

By: Naweko San-Joyz
Submitted: 2007-01-17 16:18:13
Print this article | Tell a friend | For publisher | Social Bookmarking
Rating:
 

Medical professionals and acne-pestered adolescents have no doubts about the effectiveness of the severe acne drug isotretinoin. It’s the looming possibility of side effects such as depression and fetal damage that makes people uneasy when considering using this medication.

Accutane (isotretinoin) is one of Hoffman-LaRoche’s most popular and controversial pharmaceuticals. This week, a study published in the Archives of Dermatology vindicated isotretinoin from causing depression. In this report, Christina Y. Chia, MD, from Saint Louis University Health Sciences Center, St. Louis, and colleagues examined whether patients with moderate to severe acne treated with isotretinoin experienced an increase in depressive symptoms compared with patients treated with a topical antibiotic, topical retinoid, and an oral antibiotic.

Dr. Chia found that “The use of isotretinoin in the treatment of moderate-severe acne in adolescents did not increase depressive symptoms. On the contrary, our study shows that treatment of acne improves depressive symptoms”.

Five years earlier, in 2000, the isotretinoin-depression link still appeared misleading. That time, the Archives of Dermatology posted study, headed by Dr. Susan S. Jick, from the Boston University School of Medicine, which found no evidence that isotretinoin increases the risk for depression, suicide, or other psychiatric disorders.

Even though isotretinoin finds ample support among dermatologists and psychiatrists, a host of parents, politicians and medical professionals hail isotretinoin as a medical misfortune. For instance, Dr. David J. Graham, the Associate Director for Science and Medicine in FDA’s Office of Drug Safety, recently warned that Accutane should be taken off the market.

And while there are few studies with any negative observations about isotretinoin, Dr. Douglas Bremner’s research at of the Emory University School of Medicine has linked isotretinoin treatment with changes in brain function. At the conclusion of this study, published in the American Journal of Psychiatry, Dr. Bremner concurred with Dr. Graham’s view that isotretinoin proves too dangerous for human use.

Dr. Bremner explains that to invoke depression, isotretinoin must influence the brain. During the investigation, brain function of the subjects was measured using positron emission tomography (PET) before and after four months of treatment with isotretinoin. Isotretinoin treatment was associated with decreased brain metabolism in the orbitofrontal cortex- the area of the brain known to mediate symptoms of depression. Yet, there were no differences in severity of depressive symptoms between the isotretinoin and antibiotic treatment groups before or after treatment.

The pessimistic effects of isotretinoin also caught the attention of Diane K. Wysowski PhD. Dr. Wysowski noted that in June 2000, isotretinoin ranked among the top 10 drugs linked to depression and suicide attempts in the FDA's Adverse Event Reporting System database. In 2001, Dr. Wysowski examined isotretinoin’s depression inducing potential and posted her findings in the Journal of the American Academy of Dermatology.

Dr. Wysowski concluded that more studies of isotretinoin are needed. She also advised patients and their parents to immediately report mood swings and symptoms that are suggestive of depression such as sadness, crying, loss of appetite, unusual fatigue, withdrawal, and inability to concentrate to their prescribing physician. These protective measures can avoid more serious side effects and permit appropriate treatment, including consideration of drug discontinuation and referral for psychiatric care.

While dissension among researchers still exists about whether or not isotretinoin causes depression, one idea most of them can agree on is that more research on the side effects of isotretinoin are desirable. If you are not in the mood for being an isotretinoin guinea pig, Geoffrey Redmond MD, author of The Good News about Women’s Hormones, suggests using hormone therapy and/or using Retin-A if isotretinoin seems too chancy for you.

Health author and Stanford University graduate Naweko San-Joyz lovingly writes from her home in San Diego. Her works include “Acne Messages: Crack the code of your zits and say goodbye to acne” (ISBN: 0974912204) and the upcoming work “Skinny Fat Chicks, Why we’re still not getting this dieting thing” (ISBN: 0974912212) for release in June of 2005. For useful acne self-help articles visit http://www.Noixia.com

Article source: Expert Articles

Most Recent Articles in Depression category

  • Work Stress? It's a State of Mind - By: Sandra Prior
    It may be that events at work conspire against you - but it's how you respond to them that makes all the difference. It all comes down to attitude. Each of our attitudes is like a pebble thrown into the still waters of the pond, creating a ripple effect all around us.
  • What Can Be Done about Depression in Alzheimer's Disease? - By: John Scott
    The article considers whether there is any evidence that Zoloft may assist people who have Alzheimer's Disease and are depressed. It concludes that the limited evidence is quite encouraging.
  • Learning from the past - By: John Scott
    The article looks back to 1994 when the cost of anxiety disorders to the US economy was $65 billion. Because public health care is underfunded, treatments have focused on oral medications as the cheap solution rather than expensive behavioural therapy which has a better chance of a cure.
  • A new study shows insomnia is more persistent - By: John Scott
    The article considers a twenty year study into insomnia which found that sleep loss continued and worsened over time, and that it was often followed by depression.
  • What is the story behind pre-emption? - By: John Scott
    The article visits the thorny legal question of pre-emption in relation to the liability of drug companies. It concludes that the Supreme Court should allow people injured by medications to sue.
  • How do you stay at the top of your league? - By: John Scott
    The article notes that the Neurogen Corp., a biotech company based in Connecticut, has just laid off forty-five staff and raised $30m so that it can afford to pay for the trials to prove the worth of a competitor to Ambien (and three other medications). Is the gamble worth the jobs of forty-five employees?
  • Instead of counting sheep, we should be counting prescriptions - By: John Scott
    The article wonders why insomnia seems to have become an epidemic. Millions of prescriptions a day are written around the world. Perhaps it is the 24/7 lifestyle or that we worry too much. Whatever it is, the world as a whole is suffering from lack of sleep.
  • Should DUI Become DUIA? - By: John Scott
    The articles notes a paper presented in the March meeting of the American Academy of Forensic Science which identified ambien as one of the top ten drugs found in blood samples following arrests for traffic offences. It seems that "sleep driving" may be a new danger to other road users.
  • Prejudice and disability - By: John Scott
    The article reflects on the nature of disability and considers why many for suffer from anxiety and panic attacks fail to complete the course of treatment
  • Effectiveness of Warnings Put out by the FDA and Health Canada - By: John Scott
    The article looks at two decisions in the US courts and some new Canadian research about the effectiveness of warnings put out by the FDA and Health Canada. It seems that the warning about the risk of suicide when taking SSRIs were inadequate but pre-emption prevents a tort claim in the US.